Veracyte is a leading genomic diagnostics company that develops and commercializes molecular diagnostic tests to help physicians make better treatment decisions for patients with cancer and other diseases. The company's flagship products include the Afirma thyroid cancer test, Percepta bronchial genomic classifier for lung cancer, and Prosigna breast cancer prognostic test. These tests use advanced genomic sequencing and machine learning algorithms to provide actionable information that can reduce unnecessary procedures and guide personalized treatment plans. Veracyte has established partnerships with major healthcare systems and continues to expand its test menu across multiple cancer types. The company went public in 2013 and has grown through both internal development and strategic acquisitions.
Veracyte has received investment from 11 venture capital firms.
Genomic diagnostics company that develops molecular tests to help physicians make treatment decisions for patients with thyroid, lung, and breast diseases.
Veracyte has received investment from 5AM Ventures, Accomplice, Anthos Capital, Arboretum Ventures, F-Prime Capital and 6 other investors. These venture capital firms and investors provide both capital and strategic support.
Veracyte has raised $142M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Veracyte was founded in 2008 and is headquartered in South San Francisco, CA.
Veracyte operates in the Biotech sector. Genomic diagnostics company that develops molecular tests to help physicians make treatment decisions for patients with thyroid, lung, and breast diseases.
